| 摘要 |
<p>Use of the compounds of formula (I) wherein R1 is halogen, phenyl or alkyl and R2 is hydrogen, halogen, alkyl, alkoxy or trifluoromethyl, in free form or salt form, in the treatment of IgE-mediated diseases, including i.a. chronic transplant rejection. The compounds of formula (I) are partly known. A subgroup thereof, namely the compounds of formula (Ib) wherein either R1' is halogen of atomic number 17 or 35 and R2' is hydrogen or alkoxy, or R1' is phenyl or alkyl and R2' is hydrogen, halogen, alkyl, alkoxy or trifluoromethyl, is novel and possesses remarkable cell type specificity. The compounds of formula (Ib) may be prepared e.g. by chlorination or bromination in adjacent position to an N-oxido group or by reaction of the resultant chloro or bromo compound with an organometallic compound.</p> |
